Arrythmias Clinical Trial
Official title:
Phase III Pilot Study - A Simple Randomized Trial of Conventional Versus Multimodal Prevention of Arrhythmia Device Infection
The goal of the pilot study is to compare conventional antibiotic therapy to an aggressive antibiotic therapy plan for the prevention of arrhythmia device infection in high-risk patients undergoing arrhythmia device procedures. All antibiotics are approved for use and readily available.
Infection can occur after surgery for either a pacemaker or an implantable defibrillation
and can have very serious consequences. These infections are common and can be seen in as
many as 2-3% of high-risk patients. Doctors use antibiotics to prevent these infections, but
we do not know how much or how often to give the antibiotics to get the best effect. It is
not known whether additional antibiotics during and after the operation would further reduce
the risk of infection. This research study will compare two different ways of using common
antibiotics to prevent infection during and following a device procedure. One way is the
standard approach of a single dose before surgery and the other way uses more antibiotics.
We do not know if either way is better. The purpose of this study therefore, is to compare
two types of antibiotic therapy plans to better understand if one is most effective in
preventing infection.
This study will provide the ability to evaluate the feasibility (i.e. site activation,
enrollment, compliance, drop-out) and generate proof of concept for the larger clinical
trial of 12,000 patients in all 25 Canadian Hospitals implanting ICDs, which will be
submitted to the CIHR. Additionally, the study supports the continued initiatives of the
network of physician investigators (Canadian Heart Rhythm Society Device Advisory Committee
- CHRS DAC) collaborating to address arrhythmia procedures related clinical trials that will
answer simple clinical questions that will focus initially on safety issues.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00015574 -
Air Pollution and Implantable Cardioverter Defibrillators
|
N/A | |
Recruiting |
NCT06260384 -
Wolf-Parkinson-White Syndrome and Asymptomatic Pre-excitation in Africa (a Multicenter WPW African Registry)
|